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Abstract
Background: Altered expression of receptor tyrosine kinases (RTKs) is a major driver of growth and metastasis of
cancers. Recepteur d’origine nantais (RON) receptor is a single-pass transmembrane RTK aberrantly expressed in a
number of cancers. Efforts to block deregulated RON signaling in tumors using small molecule kinase inhibitors or
antibodies are complicated by the presence of unknown number/types of isoforms of RON, which, despite having
similar sequences, are localized differently and mediate varied functions. The objective of this study was to identify
splice variants of RON transcripts between exons 1 and 10 that code for the extracellular region.
Methods: Direct cDNA sequencing was performed for the transcript between exons 1–10 of RON by Sanger
sequencing in various lung cancer cell lines.
Results: PCR amplification and bi-directional sequencing of cDNA for section between exons 1 and 10 from lung
cancer cell lines revealed the presence of several splice variants of RON transcripts; the variants were formed by
skipping of exons 2, 2–3, 5–6, 6 and 8–9. Each of these transcript variants were found in one or more cell lines.
While the variants formed by skipping of exons 2, 2–3 and 5–6 resulted in loss of 63, 106 and 109 amino acids,
respectively, and didn’t cause reading-frameshift, the transcripts formed by skipping of exons 6 and 8–9 caused
reading-frameshift. Splice variant lacking exons 8–9 was found in 13 out of 23 cell lines tested.
Conclusion: Lung cancer cell lines contain several splice variants of RON which involve skipping of exons coding
for extracellular region. Some of the splicing changes result in reading-frameshift and the N-terminally truncated
isoforms are expected to be secreted out. The ubiquitous nature of alternative splicing events in RON suggests the
need for isoform specific approaches to functional analysis and therapeutic targeting of RON.
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Background
RON is a member of the Met family of receptor tyrosine
kinases (RTKs) and ample evidence suggests its deregu-
lated expression and functioning in a number of cancers.
RON is overexpressed in cancers involving organs such as
skin, colon, breast, lung and kidney [1–8] and its overex-
pression has been shown to be associated with tumor ag-
gressiveness and metastasis [9]. Knockdown of RON
expression in different cancer cell lines using siRNA/
shRNA suppressed tumorigenic properties [10–12]. Valid-
ation of overexpressed RON as therapeutic target, how-
ever, has been hampered by the production of several of
its isoforms by tumors. Several alternatively spliced tran-
scripts and their protein products have been described for
RON in various cancer cell lines as well as in solid and
pleural tumors [13]. Differential localization of RON iso-
forms has been confirmed by their presence in the tumor
microenvironment, cytoplasm and nucleus [14–16]. Re-
cently, Western blotting studies indicated the presence of
several RON isoforms in each of several lung cancer cell
lines, while many of these same cell lines did not contain
wild type RON [15].
The alternatively spliced transcripts of RON, which
are formed by skipping of one or more exons, and their
isoform products, show considerable sequence similarity
with each other and to the wild type, despite exhibiting
diverse functionalities in cancers. The isoforms include
both hyperactive [2, 8, 17] and N-terminally truncated
dominant negative variants [13, 18–20]. Notably, ectopic
expression of some of the RON splice variants in
NIH3T3 cells lead to tumor formation in vivo [13].
Recently, we reported the presence of several, fre-
quently occurring novel transcript variants involving
exons coding for the intracellular region of RON in lung
cancer cell lines [21, 22]; the current study was designed
to identify the splicing variants that affect the extracellu-
lar region of RON using lung cancer cell lines.
Methods
Cell lines
SCLC cell lines H526 (CRL-5811), H446 (HTB-171),
H249 (CRL-5827), H69 (HTB-119), H2171 (CRL-5929),
H345 (HTB-180), H82 (HTB-175), H146 (HTB-173),
H889 (CRL-5817) and H524 (CRL-5831), and NSCLC
cell lines SW1573 (CRL-2170), H358 (CRL-5807), A549
(CCL-185EMT), H1838 (CRL-5899), H661 (HTB-183),
H522 (CRL-5810), H1437 (CRL-5872), H2170 (CRL-
5928), SW900 (HTB-59), H1993 (CRL-5909), SKLU-1
(HTB-57), H1703 (CRL-5889) and SKMES (HTB-58)
were obtained from ATCC (Manassas, VA) and were
cultured in RPMI 1640 medium (Gibco/BRL) supple-
mented with 10% (v/v) fetal bovine serum supplemented
with L-glutamine and 1% (v/v) penicillin/streptomycin at
37 °C with 5% CO2.
cDNA preparation, PCR and sequencing
Total RNA from the cell lines was isolated using TRIzol
reagent (Invitrogen, Carlsbad, CA, USA) following man-
ufacturer’s instructions. cDNA was synthesized using
1 μg of total RNA and oligo-dT primers by using Single
Strand cDNA Synthesis Kit (Clontech, Palo Alto,
CA,USA). cDNAs were PCR amplified using two pairs
of RON specific PCR primers; first PCR reaction ampli-
fied 1187 nucleotides of RON reference mRNA sequence
(NM_000247) with forward primer (located in exon 1)
5′-CAACTTGCCACTGAGCTGAGCATC-3′ and re-
verse primer (located in exon 7) 5′-CAATGGGACT
GAGTGTCTGCTAGC-3′; the second PCR reaction
amplified 789 nucleotides of RON reference mRNA se-
quence with forward primer (located in exon 6) 5′-
GAGGAGTTTGAGTGTGAACTGGAG-3′ and reverse
primer (located in exon 11) 5′-CACGTTGATACCCA
CACAGTCAGC-3′. PCR reactions were carried out
using Phusion high fidelity DNA polymerase (New Eng-
land Biolabs, MA). PCR conditions were: initial denatur-
ation at 98 °C for 30 s followed by 30 cycles of i)
denaturation at 98 °C for 10 s, ii) annealing at 60 °C for
20 s and iii) extension at 72 °C for 15 s. PCR products
were treated with EXO-SAP-IT (USB, Cleveland, OH) to
remove excess primers, following the manufacturer’s in-
structions and sequenced bi-directionally using the same
PCR amplification primers. Sequencing was performed
by employing Big Dye Terminator Chemistry (Applied
Biosystems, Weiterstadt, Germany). Sequence deletions
in the PCR products were identified by aligning sequen-
cing chromatograms with reference RON sequence
using Mutation Surveyor version 3.1 software (SoftGe-
netics, State College, PA). The nucleotide position num-
bering is relative to the first base of the translation
initiation codon of the full-length RON coding sequence
(CCDS 2807.1).
Results
Several alternatively spliced forms of RON transcripts
and their protein products have previously been re-
ported. However, PCR amplification and sequencing of
the entire coding sequence (4200 bps, consisting of 20
exons) might have failed to provide a complete picture
of all the alternative splicing events due to the formation
of multiple products, which are expected to be similar in
sequence except for one or a few missing exons. Hence,
we determined the splicing alterations involving exon(s)
skipping by amplification of two short, overlapping sec-
tions of RON cDNA, which together code for the
complete extracellular portion of wild type RON protein.
Results are summarized in Table 1.
Sequencing from 5′ end of 1187 bps RON cDNA PCR
products of cell lines indicated the presence of an overlap-
ping sequence starting at nucleotide 1231 (immediately
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following exon 1) of RON reference sequence (Fig. 1A).
The new sequence that appeared following exon 1 exactly
matched with that of exon 4 of reference sequence sug-
gesting the skipping of exons 2 + 3 in some of the RON
transcripts. The exons 2 + 3 skipping splicing variant was
found to be present together with the wild type RON tran-
script in cell lines H249, H69 and H526.
Additionally, sequencing from 5′ end of 1187 bps PCR
products also showed the appearance of two overlapping
sequences starting at nucleotide 1231 of RON reference
sequence (Fig. 1B). Of the two overlapping sequences,
one matched with that of exon 3 while the other
matched with that of exon 4, suggesting the presence of
two unique splicing alterations; one formed by skipping
of exon 2 and the other formed by skipping of exons
2 + 3. H82 was the only cell line that contained both
these splice variants along with the wild type transcript.
Sequencing the 1187 bps PCR products from the 5′
end also showed the appearance of an overlapping se-
quence starting at nucleotide 1720 of RON reference se-
quence (Fig. 1C). The newly appearing overlapping
sequence matched with that exon 7 suggesting the pres-
ence of a splice variation involving skipping of exons
5 + 6, together with the wild type RON transcript. The













2 1231–1419 189 No No 63 1
2–3 1231–1548 318 No No 106 4
5–6 1720–2046 327 No No 109 1
6 1881–2046 166 Yes Yes 6
8–9 2184–2439 256 Yes Yes 13
Fig. 1 Identification of splice variants of RON transcripts in lung cancer cell lines by PCR amplification and sequencing of cDNAs. a) RON splice
variant lacking exons 2 and 3 in cell line H249. Sequencing from 5′ end showed an additional overlapping sequence starting at nucleotide 1231
of RON reference sequence and the overlapping sequence corresponded to 5′ starting sequence of exon 4. b) RON splice variants lacking exon 2
and exons 2–3 in cell line H82. c) RON splice variant lacking exons 5 and 6 in cell line H524. This indicated the presence of a splicing variant
caused by the combined loss of exons 5 and 6 and direct splicing of exon 4 with 7. d) RON splice variant lacking exon 6 in cell line H358. This
indicated the presence of a splicing variant caused by loss of exon 6 and direct splicing of exon 5 with 7. e) RON splice variant caused by
combined loss of exons 8 and 9 in cell line SW900. This indicated the presence of only the splicing variant resulting from the combined loss of
exons 8 and 9 and direct splicing of exon 7 with 10
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exons 5 + 6 skipping splice variant was detected only in
cell line H524.
In some cell lines, sequencing the 1187 bps PCR prod-
ucts from the 3′ end showed the appearance of an over-
lapping sequence starting at nucleotide 2046 of RON
reference sequence (Fig. 1D). The overlapping sequence
matched with that of exon 5 suggesting the presence of a
splice variant formed by skipping of exon 6. RON splice
variant formed by skipping of exon 6, which was present
along with wild type RON transcript, was found in cell
lines H358, H661, SW900, H522, H526 and H146.
Sequencing the 789 bps PCR products of lung cancer
cell lines from 3′ end showed an abrupt change of se-
quence from nucleotide 2441 of RON reference se-
quence, and the new sequence matched with the 5′
sequence of exon 7 (Fig. 1E). This implied the presence
of a splice variant resulting from the combined loss of
exons 8 and 9 due to direct splicing of exon 7 with 10.
Further, in addition to the direct splicing of exon 7 with
10, a codon CAG was also retained from the intron be-
tween exons 9 and 10. RON splice variant formed by
skipping of exons 8–9, together with its wild type se-
quence, was found in cell lines H358, H661, H146,
H524, A549, H1437, H2170, SKLU1, H249, SKMES,
H69 and H522. However, in cell line SW900, normally
spliced wild type RON variant was not found in cell line
SW900, while exons 8 + 9 skipping variant was detected.
The specific exons involved/skipped in alternative spli-
cing are shown schematically in Fig. 2, in the context of
full length structure of RON protein (showing constitu-
ent domains) and coding sequence of RON transcript
(showing the constituent coding exons). Also, a supple-
mentary table (Additional file 1: Table S1) is presented
showing all the splicing variations of RON identified so
far in our lab (including this study and previous two re-
ports [21, 22]) using lung cancer cell lines.
Discussion
Aberrant expression of RON in tumors involves frequent
alternative splicing of transcripts leading to the forma-
tion of several isoform products which differ in their
functionalities. However, high similarity among the
structures of transcript variants or the protein isoforms
poses problems in therapeutic target discovery and valid-
ation. In this study, we screened lung cancer cell lines
for splice variants between exons 1 and 10 of RON tran-
scripts through partial cDNA amplification by PCR and
sequencing. Results revealed the presence of splice vari-
ants lacking exons 2, 2–3, 5–6, 6 and 8–9 in lung cancer
cell lines. Of these, skipping of exons 2, 2–3 and 5–6
merely involved loss of 63, 106 and 109 amino acids, re-
spectively, but did not cause frameshift; however, splice
variants formed by skipping of exons 6 and 8–9 resulted
in frame-shift together with the appearance of premature
termination codons.
Alternative pre-mRNA splicing that eliminates exon 2
resulting in in-frame deletion of 63 amino acids in the
extracellular domain of the RON β chain caused the
production of a 165 kda variant that localized in the
intracellular compartment [23]. Although it lacked tyro-
sine phosphorylation activity, the RONΔ165E2 variant
was shown to phosphorylate and activate phosphatase
and tensin homolog (PTEN). In the human colorectal
cancer cell line HCT116, an in-frame deletion of 106
amino acids in the extracellular domain of RON β-chain
caused by the deletion of exon 2 and exon 3 was shown
to result in the production of a 160 kDa RON isoform,
RONΔ160(E2E3), that localized intracellularly [24]. This
Fig. 2 Schematic diagram of splice variants of extracellular coding region of RON. a) Two juxtaposed Y1238 and Y1239 in the kinase domain;
phosphorylation sites Y1353 and Y1360 in the C-terminal docking site for multiple substrates with src homology 2 (SH2) domain; the other important
motifs/domains are secretory peptide signal sequence, sema, plexin, semaphorin and integrin (PSI), Ig-like, plexins, transcription factors
(IPT), transmembrane (TM) and tyrosine kinase (TK). b) 20 coding exons of RON shown in proportion to sequence length. c) 1187 bps
PCR amplicon sequenced in the present study. d) 789 bps PCR amplicon sequenced in the present study. e) Specific, skipped exons by
RON cDNA in lung cancer cell lines, as identified by PCR amplification and sequencing in the present study are: exon 2 (189 bps); exons
2 + 3 (318 bps); exons 5 + 6 (327 bps); exon 6 (166 bps) and exons 8 + 9 (256 bps)
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isoform had no tyrosine phosphorylation ability, but it
could constitutively activate Akt activity in transfected
HEK293 epithelial cells. Splicing changes affecting the
extracellular region have been shown to form dominant
negative isoforms of RON, either secreted or intracellu-
lar, in cancers. Variant RONΔ85 is a soluble/secreted
protein derived from a differentially spliced mRNA tran-
script arising out of retention of 49 nucleotide intron se-
quence between exons 5 and 6 [25]. RONΔ90 is another
secreted RON isoform, coded by a transcript lacking
exon 6 and as a result is N-terminally truncated [18].
Both these isoforms were detected in conditioned media
in in vitro cell culture studies and were shown to be cap-
able of binding both MSP and RON and block MSP/
RON signaling. RON160 is a previously reported splice
variant generated by deletion of 109 amino acids
encoded by exons 5 and 6 [13, 20]. RON160 showed
cell-transforming activities in cell focus formation and
mediated anchorage-independent growth and RON160-
mediated EMT was shown to be associated with in-
creased motile/invasive activity [26]. In our study, spli-
cing involving loss of exons 5–6 was only identified in 1
of 23 lung cancer cell lines indicating that this is not a
common occurrence in lung cancer.
The splice variants formed by skipping of exon 6 and
exons 8–9 result in reading frame-shift and were found
in several cell lines examined in this study. RON tran-
scripts with combined deletion of exons 8 and 9 have
not been reported previously. Deletion of exons 8 + 9 re-
sult in the appearance of a premature termination
codon; this may lead to the absence of the transmem-
brane sequence, which is coded by exon 12 of wild type
RON; consequently, the N-terminally truncated peptide
with most of the extracellular sequence of wild type
RON may be secreted out. However, the transcript
variants caused by loss of exons without concurrent
frame-shift may lead to constitutively active or dominant
negative activities. We speculate that the secreted RON
isoforms may also bind and dimerize wild type RON lo-
cated on the surface of tumor cells or on cells such as
macrophages of the tumor microenvironment. MSP-
RON signaling in macrophages suppresses inflammation
by downregulating iNOS and COX-2 expression and in-
creasing the production of the anti-inflammatory cyto-
kine IL-10 [27–29]. Hence, the soluble RON isoforms
circulating in blood may serve to increase inflammation
in distant organs, an important hallmark of cancer, and
thereby facilitating metastasis.
Results from the present and the two earlier studies
(performed in our lab) [21, 22] on RON splicing changes
involving skipping of exons using lung cancer cell lines
has revealed that incidence of splice variants is common
in lung cancer. RON transcripts in H82 cell line showed
splice variations at 7 locations suggesting their possible
occurrence in various combinations in full length tran-
scripts. H249, SW900, H526, H69, H524, A549 and
H358 were the other cell lines that contained 4 or more
alternative splicing events. Also, a majority of the exons
of RON that were analyzed in these studies were in-
volved in alternative splicing. Furthermore, in agreement
with the identification of multiple alternatively spliced
RON transcripts, our previous work showed the pres-
ence of multiple RON isoforms of different sizes in sev-
eral lung cancer cell lines as identified by Western
blotting [15].
This study was mainly focused on evaluating the inci-
dence of splicing changes which may interfere with the
qualitative and quantitative outcomes of various methods
currently employed to study the role of RON signaling in
cancer. Amplification and sequencing of smaller regions
of the coding cDNA sequence has proved powerful
enough to reveal the presence of several alternatively
spliced mRNA transcripts in lung cancer that may have
been missed by other methods. The results of this and the
other two previous studies [21, 22] strongly suggest that
the presence of various alternatively spliced mRNA tran-
scripts and their isoform products must be taken into con-
sideration while correlating expression of wild type RON
to its functions in lung cancer.
Conclusions
Alternative splicing is a major general mechanism of
genetic alteration used by cells to increase the repertoire
and the functions of proteins and cancer cells stand to
gain significantly by using this mechanism. Even though
more than 90% of known transcripts are understood to
undergo alternative splicing, this fact, which can inter-
fere with both qualitative and quantitative methods, is
not given due consideration in basic research or during
target validation studies. Identification of several alterna-
tively spliced variants together with the structural data
from this study shed light on the frequent and ubiqui-
tous nature of alternative splicing in RON in lung cancer
and suggests that isoform specific quantification and
functional determination may be an important pre-
requisite for understanding the deregulated RON signal-
ing in cancers.
Additional file
Additional file 1: Table S1. Summary of splice variations identified in
lung cancer cell lines. (DOCX 14 kb)
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